NEO as reported
NeoGenomics, Inc. reported $766M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed.
$766M
Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before
- Net Income
- −$52M
Net Income · −50% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$7.4M
Free Cash Flow · −62% year on year · trailing twelve months to Q2 2026
- Op Margin
- −9.0%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $766M | +11% | Q2 2026 |
| Net Income | −$52M | −50% | Q2 2026 |
| EPS | −$0.39 | −52% | Q2 2026 |
| Gross Margin | 44% | n/a | Q2 2026 |
| Op Margin | −9.0% | n/a | Q2 2026 |
| Net Margin | −6.9% | n/a | Q2 2026 |
| ROE | −11% | n/a | Q2 2026 |
| ROA | −6.9% | n/a | Q2 2026 |
| ROIC | −4.6% | n/a | Q4 2021 · 18 quarters behind |
| Free Cash Flow | −$7.4M | −62% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
NeoGenomics, Inc. (NEO) - Revenue & ProfitRevenue & ProfitNeoGenomics, Inc. (NEO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #7 of 29 by Smart Score